Chr. Hansen Holding A/S (0MR6.L)
| Previous close | N/A |
| YTD return | N/A |
| Expense ratio (net) | N/A |
| Category | N/A |
| Last cap gain | N/A |
| Morningstar rating | N/A |
| Morningstar risk rating | N/A |
| Sustainability rating | N/A |
| Net assets | N/A |
| Beta (5Y monthly) | N/A |
| Yield | N/A |
| 5y average return | N/A |
| Holdings turnover | N/A |
| Last dividend | N/A |
| Average for category | N/A |
| Inception date | N/A |
- Globe Newswire
Lillie Li Valeur steps down from the Board of Directors
Company announcement no. 04/2022 April 25, 2022 Please see attachment. For further information, please contact:Anders Mohr Christensen, Vice President Group Strategy & Investor Relations, Tel: +45 2515 2364Annika Stern, Senior Investor Relations Manager, Tel: +45 2399 2382Sanne Seyer-Hansen, Head of Media Relations, Tel: +45 6038 6207 About Chr. HansenChr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical an
- Globe Newswire
Chr. Hansen Holding A/S Interim Report Q2 2021/22
Company announcement no. 03/2022 April 6, 2022 Strong Q2 growth in a challenging environment Statement by CEO Mauricio Graber: “In a challenging environment, Chr. Hansen continued its strong growth trajectory, delivering 14% organic growth in the second quarter. Growth in Health & Nutrition further accelerated, supported by Human Health, while Food Cultures & Enzymes showed solid growth, mainly driven by its core segments and developed markets. In the second quarter, the EBIT margin b.s.i. incre
- Globe Newswire
Chr. Hansen Holding A/S Interim Report Q1 2021/22
January 13, 2022 Company announcement no. 1 Solid start to the year Statement by CEO Mauricio Graber: “The encouraging start to the year with organic growth of 9% and progress across all business areas and strategic initiatives underlines the strength of our 2025 strategy differentiating us as a bioscience company focused on microbial and fermentation technology platforms. Food Cultures & Enzymes continued its strong momentum in the first quarter, while Health & Nutrition delivered a strong reb
